Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMK2RIB)

Drug Name

GTB-3550 Drug Info

Synonyms

OXS-3550

Indication

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Phase 1/2	[1]
Mast cell leukaemia	2A21.00	Phase 1/2	[1]
Myelodysplastic syndrome	2A37	Phase 1/2	[1]
Systemic mastocytosis	2A21.0	Phase 1/2	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Immunoglobulin gamma Fc receptor III (FCGR3)	TT7KTSR	FCG3A_HUMAN; FCG3B_HUMAN	Inhibitor	[2]
Myeloid cell surface antigen CD33 (CD33)	TTJVYO3	CD33_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Myeloid cell surface antigen CD33 (CD33)	DTT	CD33	2.485	2.744	2.868	2.744

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Acute myelogenous leukaemia

ICD Disease Classification

2A41

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Myeloid cell surface antigen CD33 (CD33)	DTT	CD33	5.37E-13	0.58	1.13

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03214666) GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for High Risk Heme Malignancies. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of GT Biopharma.